Advertisement

Topics

ACTIVAERO APPOINTS CHRISTIAN PANGRATZ AS NEW CHIEF BUSINESS OFFICER.

05:44 EDT 16 May 2011 | BioPortfolio

Gemünden (Wohra), Germany – May 16, 2011- Activaero GmbH, a leader in controlled breathing inhalation technologies and therapeutics, today announced the appointment of Christian M. Pangratz as Chief Business Officer.

Mr. Pangratz joins Activaero from Nektar Therapeutics, San Francisco where he recently served as Executive Director of Business Development. He brings to Activaero 20 years of commercial life science experience and has developed an excellent track record in global deal making for various indications.

As Chief Business Officer, Mr. Pangratz will join the Activaero Management Team and will lead all business development, marketing and alliance management activities.

Gerhard Scheuch, founder and CEO of Activaero said: “The creation of a new full-time business development position is the consequence of the excellent progress of our clinical development programs and our recent organizational growth. We welcome Mr. Pangratz to our leadership team and we are convinced that his expertise will bring a strong new perspective to our commercial efforts.”

Christian Pangratz will replace Dr. Henrik Luessen as Chief Business Officer. While Dr. Luessen decided to re-focus on his own consultancy firm (www.tytonis.com), he will continue to support Activaero’s business development team on a part time basis.

Mr. Pangratz added: “Activaero’s Favorite Technology Platform has demonstrated unparalleled performance in various partnerships as well as in Activaero’s high value clinical development programs. This platform addresses the key challenges and unmet needs in the treatment of severe lung diseases. I am excited to join and help the Activaero team to further grow the company based on the huge potential of its platform technology and proprietary product pipeline.”

About Activaero:
Activaero is a leader in controlled breathing inhalation technologies and therapeutics. These innovative technologies enable safer, more cost-efficient, and effective options for inhaled treatments of respiratory diseases and are available for clinical trials and pharma partnerships. Under the trade mark of AKITA® Activaero is developing and producing inhalation systems which enable the use of FAVORITE in the therapy of pulmonary diseases and the development of new inhalant drugs. Beyond that, Activaero is a center of excellence in aerosol medicine and supports pharma and biotech companies with its technology and services. Activaero GmbH is located in Gemuenden/Wohra and Munich (Germany) and Dublin, Ohio (USA).

Activaero
Axel Fischer
Managing Director
t: +49 (0)6453 – 64818 – 0
e:axel.fischer@activaero.de
www.activaero.com

Dr. Robert Mayer
Senior Account Manager
College Hill Life Sciences
t: +49 (0)89 52 38 80 30
e: robert.mayer@collegehill.com

NEXT ARTICLE

More From BioPortfolio on "ACTIVAERO APPOINTS CHRISTIAN PANGRATZ AS NEW CHIEF BUSINESS OFFICER."

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...